With their shares having surged by more than 484%, 500% and 275%, respectively, the three stocks highlighted in today’s article are three of the best-performing pharmaceutical stocks over the past year – and despite them having already experienced monster moves higher, it may not be too late to get in on these stocks’ gains. For more on these three pharmaceutical stocks, how much higher each can possibly go, and which may be the safest (and the riskiest) bet, CLICK HERE.
The Fed may have helped the stock market rally from the March coronavirus collapse, but the author of today’s article warns that “a new and still largely overlooked risk has emerged with the calming of the COVID-19 crisis…And if this risk starts to manifest itself going forward, it will likely bring the U.S. stock market to its knees.” What is this risk – and how can investors position themselves today to prepare for – and even capitalize on – this risk? CLICK HERE.
The man who has been ranked as the most accurate forecaster of US economic data eight years in a row by Bloomberg has some sobering warnings when it comes to the country’s recovery from the coronavirus pandemic – and how that could impact the current stock market rally. For what he has to say about how long it will take the US to experience a full recovery – and the chances of a stock market correction from August to November – CLICK HERE.
Thanks to the economic impact of the coronavirus pandemic, this earnings season may prove to be one of the most unpredictable in a long time. In this environment, a Goldman Sachs strategist advises that the most liquid stocks are likely to outperform – and so he and his team have identified the 13 most liquid S&P 500 stocks. For these stocks to consider as an unusual earnings season gets underway, CLICK HERE.
In regards to the biotech sector, the author of today’s article advises that “it makes sense to keep an eye on this general area of the market as it is likely to play an increasingly significant role not just in the fight against Covid-19 but also in the war on cancer, the battle against rare diseases, and increasingly on more common diseases where traditional treatments are running into limitations.” For what he sees as an ideal way to invest in biotech – and his recommendation on when to buy – CLICK HERE.
While the Trump administration has not publicly identified the drugmakers and biotechs involved in Operation Warp Speed – its effort to have 300 million doses of a safe and effective COVID-19 vaccine ready by January 2021 – some tiny biotechs have been touting their involvement in the program, sending their stocks soaring. For more, CLICK HERE.
Clinical trial data or regulatory verdicts can send shares of biotech companies skyrocketing – or plummeting. The question then, as the author of today’s article observes, is “how are investors supposed to determine which biotech stocks are capable of outperforming the rest?” One approach is to track analyst sentiment – and the author highlights three biotech stocks that not only are analysts bullish on but which are trading for less than $5 a share and boast upside potential of over 100%. For more, CLICK HERE.
Today’s article highlights two “compelling small-cap stocks that combine a low cost of entry with the Street’s backing.” More specifically, these two stocks – a biotech firm and a pharmaceutical company – are currently trading for less than $8 a share, have earned “Strong Buy” consensus analyst ratings, and boast significant upside potential. For more, CLICK HERE.
As the end of the second quarter of 2020 approaches, a number of biopharmaceutical companies have data readouts due – and positive trial data could serve as catalysts for those companies’ stocks. For seven biopharmaceutical companies with impending data readouts – and details on their respective potential catalysts – CLICK HERE.
“Biotech penny stocks have always been a big focus for investors but this year has been one of the most active years for the sector,” observes the author of today’s article. And while the coronavirus outbreak has been a major reason for this increased activity, the author notes that “you also have companies hitting big milestones for other health indications.” With this being perhaps one of the best times to bet on biotech penny stocks, the author highlights four in particular to have a look at. For more, CLICK HERE.